Gabapentin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Carpal Tunnel Syndrome

Conditions

Carpal Tunnel Syndrome

Trial Timeline

Oct 1, 2003 → Dec 1, 2006

NCT ID

NCT00137735

About Gabapentin

Gabapentin is a phase 3 stage product being developed by Pfizer for Carpal Tunnel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00137735. Target conditions include Carpal Tunnel Syndrome.

What happened to similar drugs?

1 of 1 similar drugs in Carpal Tunnel Syndrome were approved

Approved (1) Terminated (0) Active (0)

✅Lidocaine 1.8% + PlaceboScilex HoldingApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01441401	Pre-clinical	Completed	Dec 1, 2011	Sep 1, 2014	Epilepsies, Partial
NCT00620555	Phase 3	Completed	May 1, 2008	Dec 1, 2010	Epilepsies, Partial
NCT00603473	Phase 3	Completed	Jan 1, 2008	Dec 1, 2009	Epilepsies, Partial
NCT00567268	Pre-clinical	Completed	Aug 1, 2007	May 1, 2014	Epilepsies, Partial
NCT00659100	Phase 3	Completed	Aug 1, 2006	Jan 1, 2007	Transient Insomnia
NCT00577967	Pre-clinical	UNKNOWN	Oct 1, 2005	Mar 1, 2006	Pruritus
NCT00533455	Phase 3	Terminated	Mar 1, 2004	Aug 1, 2007	Neuroleptic-Induced Tremor
NCT00137735	Phase 3	Completed	Oct 1, 2003	Dec 1, 2006	Carpal Tunnel Syndrome
NCT00644748	Approved	Completed	May 1, 2003	Aug 1, 2004	Diabetic Neuropathies
NCT00169013	Approved	Completed	May 1, 2002	Jun 1, 2006	Amputation of Lower Limb

Competing Products

1 competing product in Carpal Tunnel Syndrome

See all competitors

Product	Company	Stage	Hype Score
Lidocaine 1.8% + Placebo	Scilex Holding	Approved	33